Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrinabdione (Primary)
  • Indications Multiple sclerosis; Systemic scleroderma
  • Focus Adverse reactions; First in man
  • Sponsors Emerald Health Pharmaceuticals

Most Recent Events

  • 19 Feb 2020 According to an Emerald Health Pharmaceuticals media release, data from this study will be presented at the upcoming ACTRIMS(Americas Committee for Treatment and Research in Multiple Sclerosis) Forum 2020.
  • 13 Jan 2020 According to an Emerald Health Pharmaceuticals media release, the company plans to announce the full data from this Phase 1 study in February at a prestigious medical meeting.
  • 26 Aug 2019 According to an Emerald Health Pharmaceuticals Media release, the company plans to announce top-line results from this study before end of 2019, once the data are fully analyzed, and will be submitting the study results for presentation at upcoming international conferences.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top